The LIPODIET pilot study is a small but clinically interesting intervention study on low-carbohydrate, high-fat nutrition in lipedema. Its core message is balanced: during seven weeks of an LCHF/ketogenic-style diet, pain decreased and quality of life improved, but the sample was very small, there was no control group, and pain returned to baseline after participants moved to Nordic nutrition recommendations (Sørlie et al., 2022). This should not be read as “ketogenic diet treats lipedema.” A safer interpretation is that carbohydrate restriction may influence pain perception and daily burden in some women with lipedema.
What question did the study ask?
The study asked whether an eucaloric, meaning weight-maintenance in intention, low-carbohydrate high-fat diet could affect pain, quality of life, body weight and body composition in women with lipedema. This matters because many patients are told that lipedema tissue is resistant to conventional diet and exercise, yet they still need realistic nutritional strategies. The discussion naturally connects to lipedema nutrition, not as a promise of cure but as part of symptom-oriented care.
Study type, method and sample
This was a prospective, single-arm pilot dietary intervention, not a randomized controlled trial. Nine women with leg-involving lipedema, aged 18-75 years and with BMI between 30 and 45 kg/m2, were included. They followed an LCHF/ketogenic-style diet for seven weeks and then a diet based on Nordic nutrition recommendations for six weeks. Pain was measured with a visual analogue scale, quality of life with a lymphedema quality-of-life questionnaire, and weight and body composition were assessed at baseline, week seven and week thirteen (Sørlie et al., 2022).
Main findings: what is repeated, new and interesting?
After seven weeks, mean weight loss was 4.6 kg and pain decreased by 2.3 cm. The most interesting finding was that pain reduction did not correlate significantly with weight loss. In this small sample, the change in pain could not be explained simply by the number on the scale. By week thirteen, weight loss was largely maintained, but pain returned to baseline. This raises hypotheses about ketosis, carbohydrate load, tissue fluid, inflammatory signaling and pain processing, but the pilot design cannot prove any of these mechanisms (Sørlie et al., 2022).
What is new is the short-term signal that pain in lipedema may respond to diet composition. What is repeated is the idea that lipedema is not only a weight problem. Pain, tenderness and daily limitation often move differently from body weight; lipedema pain remains relevant when interpreting nutrition trials.
How does it fit with later literature?
The LIPODIET signal was partly strengthened by a later randomized controlled trial. Lundanes and colleagues randomized 70 women to a low-carbohydrate or a low-fat low-energy diet and found a greater pain reduction in the low-carbohydrate arm (Lundanes et al., 2024a). A related MRI-based secondary analysis reported reductions in calf subcutaneous adipose tissue area, calf circumference and pain in the low-carbohydrate group, while both groups also showed loss of muscle area or fat-free mass (Lundanes et al., 2024b). This supports the idea that pain change may not be only weight loss, while also reminding clinicians to protect muscle through protein planning, resistance exercise and monitoring.
A 2024 systematic review and meta-analysis reported that LCHF/ketogenic interventions were associated with reductions in body weight, BMI, circumferences and pain sensitivity, but the number of studies was limited and the evidence still needs cautious interpretation (Amato et al., 2024). A 2025 systematic review was more conservative: nine studies were heterogeneous, risk of bias was often moderate to high, and the clinical effect of dietary interventions remained uncertain (de Oliveira et al., 2025). This is why the current S2k guideline’s multidisciplinary framing matters; nutrition, manual lymph drainage and compression and movement belong in the same care plan rather than competing as isolated solutions (Faerber et al., 2024).
Evidence strength and limitations
- Strength: It directly measured pain and quality of life in women with lipedema.
- Main limitation: The sample included only nine participants and lacked a control group.
- Short follow-up: The pain effect was not shown to persist after the diet change.
- Limited generalizability: Results cannot be directly applied to all stages, lean patients, older or younger groups, or long-term practice.
- Measurement issue: Pain was self-reported, which is clinically meaningful but sensitive to expectation and day-to-day variation.
What does this mean in practice?
The study suggests that keto and low-carb diet may be a reasonable option to discuss in selected patients, especially when pain and metabolic burden coexist. It still requires individual assessment: kidney and liver status, diabetes medication, pregnancy or breastfeeding, eating-disorder history, lipid profile, exercise capacity and sustainability all matter. In lipedema care, success should not be reduced to weight loss. Pain, muscle preservation, bowel tolerance, sleep, movement capacity and long-term adherence matter together.
What should patients not misunderstand?
This study does not show that ketogenic nutrition removes lipedema tissue or cures the condition. It also does not mean that lipedema disappears with weight loss; in LIPODIET, pain improved without a clear correlation with weight loss and later returned while weight loss was maintained. This makes does lipedema go away with weight loss a key clinical question. Lipedema and obesity may coexist, but they are not the same condition; lipedema vs obesity helps keep this distinction clear when reading diet studies.
What questions remain open?
The unanswered questions are important: was pain reduction driven by ketosis, lower carbohydrate intake, energy intake, tissue fluid, inflammation or a combination? Which stage or type of lipedema responds best? How can muscle loss be prevented during restrictive diets? How does the plan affect psychological burden and eating behavior? LIPODIET did not settle these questions, but it provided a useful early signal for stronger randomized trials.
